Similarly, PARP inhibitors enhance the antitumor activity of sacituzumab govitecan in triple-negative breast cancer [34] and BCL-2/XL inhibitors enhance the cytotoxicity of T-DM1 [35]. This evidence concerns the gene BCL2 and triple-negative breast carcinoma.